1. Upregulation of SATB1 is associated with the development and progression of glioma
   Sheng-Hua Chu et al, 2012, Journal of Translational Medicine CrossRef
2. Evaluation of combination gene therapy with SLC22A18 upregulation and sequence binding protein 1 downregulation for glioma U251 cells in vitro and in vivo
   Shenghua Chu et al, 2020, Glioma CrossRef
3. In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles
   S.-H. Chu et al, 2013, Neuro-Oncology CrossRef
4. Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy
   Sheng-Hua Chu et al, 2013, Journal of Translational Medicine CrossRef
5. Genetic Profiles Playing Opposite Roles of Pathogenesis in Schizophrenia and Glioma
   Ya-Dan Wen et al, 2020, Journal of Oncology CrossRef
6. microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18
   Bicheng Zhang et al, 2015, International Journal of Biological Macromolecules CrossRef
7. Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier inSDHD-linked paragangliomas:SLC22A18andCDKN1Care candidate tumour modifiers
   Attje S Hoekstra et al, 2016, Human Molecular Genetics CrossRef
8. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches
   Md. Sahab Uddin et al, 2022, Seminars in Cancer Biology CrossRef
9. In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18
   S-H Chu et al, 2014, Cancer Gene Therapy CrossRef
10. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells
    Biao Yang et al, 2018, Cancer Gene Therapy CrossRef
11. Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme
    SHENG-HUA CHU et al, 2013, Molecular Medicine Reports CrossRef